Published in Clin Immunol on July 13, 2012
Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol (2013) 1.27
Cutting edge: Leptin-induced RORγt expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol (2013) 1.00
Plasmodium falciparum erythrocytic stage parasites require the putative autophagy protein PfAtg7 for normal growth. PLoS One (2013) 0.79
Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target. Front Immunol (2015) 0.77
Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation. J Immunol (2017) 0.75
Methods in mammalian autophagy research. Cell (2010) 20.08
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J (2008) 12.89
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 10.21
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med (2000) 9.78
Systemic lupus erythematosus. N Engl J Med (2011) 7.79
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
T cell activation. Annu Rev Immunol (2009) 7.40
During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol (2011) 7.40
mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature (2007) 7.12
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J Exp Med (2006) 6.01
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol (2008) 5.55
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol (2011) 5.22
Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 4.78
A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum (1992) 4.50
The IL-23/IL-17 axis in inflammation. J Clin Invest (2006) 4.32
The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem (2006) 4.28
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem (2005) 3.74
Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol (2008) 3.65
Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum (2004) 3.57
Microautophagy of cytosolic proteins by late endosomes. Dev Cell (2011) 3.51
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 2.99
The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol (2006) 2.98
Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun (2009) 2.78
c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol (2002) 2.64
Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J Immunol (2009) 2.61
Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest (1998) 2.60
On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity (2000) 2.48
Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med (2010) 2.35
Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nat Immunol (2008) 2.34
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol (2007) 2.32
PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med (2005) 2.28
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol (1999) 2.26
How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol (1995) 2.24
Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proc Natl Acad Sci U S A (2008) 2.22
Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann N Y Acad Sci (2010) 2.20
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A (2007) 2.06
The role of IL-23/IL-17 axis in lupus nephritis. J Immunol (2009) 2.06
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis (2010) 2.05
Mitochondria removal by autophagy. Autophagy (2011) 2.04
Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem (2005) 2.00
Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus (2009) 1.97
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 1.86
Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci U S A (2009) 1.85
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum (2000) 1.84
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol (2011) 1.83
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
Autophagy and the immune system. Annu Rev Immunol (2012) 1.80
Endocytosis and recycling of the T3-T cell receptor complex. The role of T3 phosphorylation. J Exp Med (1987) 1.80
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum (2007) 1.79
The late endosome is essential for mTORC1 signaling. Mol Biol Cell (2010) 1.79
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 1.76
Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol Dis (2010) 1.75
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol (2006) 1.75
Macroautophagy regulates energy metabolism during effector T cell activation. J Immunol (2010) 1.71
Retracted Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol (2008) 1.69
Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol (2003) 1.68
Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population. Ann Rheum Dis (2011) 1.67
IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol (1998) 1.65
Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum (2011) 1.65
Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2011) 1.64
The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell Signal (2011) 1.62
Temporal regulation of intracellular organelle homeostasis in T lymphocytes by autophagy. J Immunol (2011) 1.61
Regulation of mTORC1 by the Rab and Arf GTPases. J Biol Chem (2010) 1.60
Autophagy regulates endoplasmic reticulum homeostasis and calcium mobilization in T lymphocytes. J Immunol (2010) 1.60
Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol (2004) 1.56
Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol (2008) 1.56
Autophagy and its role in MHC-mediated antigen presentation. J Immunol (2009) 1.54
Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 1.54
Rab35 and its GAP EPI64C in T cells regulate receptor recycling and immunological synapse formation. J Biol Chem (2008) 1.54
Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol (2009) 1.52
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (2009) 1.52
Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (2004) 1.52
The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol (2006) 1.49
Sustained activity of calcium release-activated calcium channels requires translocation of mitochondria to the plasma membrane. J Biol Chem (2006) 1.48
Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol (1996) 1.46
How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol (2008) 1.44
Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum (2001) 1.44
A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol (2010) 1.42
Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. FASEB J (2006) 1.42
Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. Cell Death Differ (2011) 1.42
T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol (2003) 1.39
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 1.38
B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J Immunol (2009) 1.38
TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol (1995) 1.36
Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum (1994) 1.36
Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol (2010) 2.89
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 1.76
Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest (2009) 1.75
Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum (2002) 1.62
Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 1.54
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (2009) 1.52
T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol (2003) 1.39
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
Metabolic control of T cell activation and death in SLE. Autoimmun Rev (2008) 1.28
T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol (2005) 1.27
mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med (2010) 1.21
Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem (2006) 1.16
Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum (2011) 1.13
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol (2007) 1.08
Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry (2012) 1.08
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol (2014) 1.03
Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity (2010) 1.02
Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol (2009) 0.99
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol (2013) 0.99
T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J (2012) 0.99
Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor γ. J Immunol (2012) 0.96
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol (2008) 0.96
Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum (2008) 0.95
Nitric oxide, mitochondrial hyperpolarization, and T cell activation. Free Radic Biol Med (2007) 0.94
Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol (2005) 0.93
Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol (2007) 0.93
Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene transcription-activating factor (STAF). Biochem J (2011) 0.92
ZNF143 mediates basal and tissue-specific expression of human transaldolase. J Biol Chem (2003) 0.91
Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother (2009) 0.91
Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem J (2008) 0.91
Emerging pathways of non-genomic glucocorticoid (GC) signalling in T cells. Immunobiology (2009) 0.90
Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antioxid Redox Signal (2014) 0.90
Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol (2013) 0.88
Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol (2014) 0.87
CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J Immunol (2005) 0.87
Detection of lupus anticoagulant and successful anticoagulation in familial Sneddon syndrome. Ann Rheum Dis (2010) 0.87
Possible pathogenic nature of the recently discovered TT virus: does it play a role in autoimmune rheumatic diseases? Autoimmun Rev (2006) 0.86
CCL genes in multiple sclerosis and systemic lupus erythematosus. J Neuroimmunol (2008) 0.86
Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocr Metab Immune Disord Drug Targets (2006) 0.86
Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol (2010) 0.85
DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus. Autoimmunity (2013) 0.84
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum (2013) 0.83
Bifunctional, chemically patterned flat stamps for microcontact printing of polar inks. Langmuir (2008) 0.83
Self-assembled monolayers of subphthalocyanines on gold substrates. Org Lett (2010) 0.82
Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One (2013) 0.82
Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J Immunol (2010) 0.82
Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leuk Res (2009) 0.81
The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clin Immunol (2006) 0.81
Deletion of Ser-171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase. Biochem J (2004) 0.80
The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity. Br J Clin Pharmacol (2006) 0.80
Lymphoedema: a paradoxical effect of tumour necrosis factor inhibitors - case report and review of literature. BMJ Case Rep (2009) 0.77
Differential regulation of hydrogen peroxide and Fas-dependent apoptosis pathways by dehydroascorbate, the oxidized form of vitamin C. Antioxid Redox Signal (2002) 0.77
Metabolic control of the epigenome in systemic Lupus erythematosus. Autoimmunity (2013) 0.76
The role of endocytic recycling in autoimmunity. Methods Mol Biol (2012) 0.76
Overview of signal processing by the immune system in systemic lupus erythematosus. Autoimmun Rev (2008) 0.75
Oxidative stress and endosome recycling are complementary mechanisms reorganizing the T-cell receptor signaling complex in SLE. Clin Immunol (2011) 0.75
Phase transfer of CdS nanocrystals mediated by heptamine β-cyclodextrin. Langmuir (2012) 0.75
Surface modification of elastomeric stamps for microcontact printing of polar inks. Langmuir (2007) 0.75
Evaluation of autoimmunity to transaldolase in multiple sclerosis. Methods Mol Med (2004) 0.75
Palpable purpura, polyarthritis and abdominal pain. Med J Aust (2004) 0.75
Computational methods for functional site identification suggest a substrate access channel in transaldolase. Genome Inform (2006) 0.75